PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28630385-10	2017	CONCLUSION: Treatment by lenalidomide and pcDNA3.1(+)/NS3 improves NK cytotoxicity up to 66.80% suggesting that lenalidomide can be used in parallel with such therapeutic vaccines as cancer vaccine or virus vaccines.	Lenalidomide	112-124	KRAS proto-oncogene, GTPase	Homo sapiens	54-57	
24351336-0	2014	Increase in antibody-dependent cellular cytotoxicity (ADCC) in a patient with advanced colorectal carcinoma carrying a KRAS mutation under lenalidomide therapy.	Lenalidomide	139-151	KRAS proto-oncogene, GTPase	Homo sapiens	119-123	
24351336-5	2014	In a heavily pretreated patient with advanced colorectal cancer carrying mutations in APC and KRAS genes, we show an early metabolic response and enhanced NK cell activity to monotherapy with lenalidomide.	Lenalidomide	192-204	KRAS proto-oncogene, GTPase	Homo sapiens	94-98	
24244261-0	2013	Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer.	Lenalidomide	59-71	KRAS proto-oncogene, GTPase	Homo sapiens	105-109	
24244261-1	2013	UNLABELLED: This study aimed to assess the efficacy and safety of combination treatment with lenalidomide and cetuximab in KRAS-mutant metastatic colorectal cancer patients.	Lenalidomide	93-105	KRAS proto-oncogene, GTPase	Homo sapiens	123-127	
24244687-0	2013	Immunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients.	Lenalidomide	48-60	KRAS proto-oncogene, GTPase	Homo sapiens	99-103